BioMedTracker

SAMPLE COMPANY PROFILE
(Data Shown as of 09/14/05)

Amylin Pharmaceuticals, Inc. (AMLN)

Pipeline Valuation

Current Market Price: $31.16
	Estimated Pipeline Value per Share:	2010	2015

	At Enterprise Value/EBITDA of 25:	46.72	55.26
Probability Adjusted Revenue (M):		1664.1	3030.9
Estimated EBITDA (M):		447.0	1179.0
Assumptions			Explanation

(View 10 Year Revenue Outlook: U.S. Worldwide)

Name	Indication	Phase	Recent Event	Likelihood of Approval	Est. Approval Date	Peak U.S. Revenue (M)	Upcoming Catalyst
Name	Indication	Phase	Recent Event	Likelihood of Approval	Est. Approval Date	Peak U.S. Revenue (M)	Upcoming Catalyst
AC162352	Obesity	I	10/20/04	25% (5% Above Avg.)	01/10	$ 416.3
AC2592	Congestive Heart Failure	II	12/05/04	27% (3% Below Avg.)	N/A	N/A
AC3056	Coronary Artery Graft Restenosis	I	06/11/02	25% (5% Above Avg.)	01/10	$ 7.3
	Cardiovascular Disease	I	06/11/02	25% (5% Above Avg.)	01/10	$ 20.6
	Percutaneous Coronary Intervention Restenosis	I	06/11/02	25% (5% Above Avg.)	01/10	$ 21.6
Byetta	Diabetes Mellitus, Type II	Approved	08/04/05	100% (Same As Avg.)	04/05	$ 897.5	10/01/05 - 12/31/05
Exenatide LAR	Diabetes Mellitus, Type II	II	08/22/05	55% (25% Above Avg.)	01/09	$ 4,007.7	Now - 06/30/06
Symlin (AC137)	Diabetes Mellitus, Type I	Approved	06/12/05	100% (Same As Avg.)	03/05	$ 24.7
	Diabetes Mellitus, Type II	Approved	08/04/05	100% (Same As Avg.)	03/05	$ 366.5	Now - 10/31/05
	Obesity	II	08/04/05	40% (10% Above Avg.)	01/08	$ 279.3	01/01/06 - 03/31/06

Biotechnology company focused on developing treatments for diabetes and other metabolic disorders. Amylin's diabetes care portfolio contains several injectable, non-insulin based hypoglycemic compounds that have generated compelling preclinical and clinical trial data. Amylin is poised to take advantage of the trend toward more aggressive anti-diabetic drug use and intensified screening of people at high risk for diabetes. This trend is prompted by the new guidelines from the American College of Endocrinology (ACE) and the American Association of Clinical Endocrinologists (AACE).

Amylin's pipeline should make it a strong player in the diabetes market, or a prime acquisition target for the existing leaders in this market. Amylin and Eli Lilly have recently forged one of the most progressive biotech / pharma deals ever, focusing upon commercial opportunities for AC2993.

Questions? Email Customer Support	Privacy Policy Important Legal Disclosure
Copyright � 2004 Sagient Research Systems, Inc. All rights reserved.